Leaders in Pharmaceutical Business Intelligence (LPBI) Group

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence will represent ALNION at 

The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum Promoting Public & Private Sector Collaboration & Investment in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Non-Invasive Lung Cancer Screening

March 2014

Alnion provides a low cost, non-invasive, point of care diagnostic tool capable of detecting early stage lung cancer with greater than 88% accuracy. The device makes use of human breath to detect Volatile Organic Compounds (VOCs), which are indicators of malignant tissue metabolism. The tool takes the form of a low cost hand held consumer electronic device, into which proprietary test cartridges are inserted for each measurement. Once the unit has captured and digitized the patient’s breath print, the data is encrypted and uploaded wirelessly to the clinician’s appliance of choice, i.e. ipad, Android phone, etc. The concept has already been proven in pilot studies, as have all manufacturing processes required for mass production. See pilot study results below:

See Quick Video: http://www.youtube.com/watch?v=CHp-ax12NT0

Alnion – A Joint Venture between ASI and Technion

– ASI provides an exceptional IP portfolio and electronics manufacturing capabilities to seamlessly industrialize such a Point of Care (POC) Appliance.

– Technion’s exhaustive biomarker characterization efforts have demonstrated unsurpassed accuracy at the clinical level, minimizing the regulatory process and learning curve in deployment.

These two attributes provide the basis for a plug and play business model comprised of a rapid time to market appliance addressing critical unmet medical needs as called for in the National Lung Screening Trials. Alnion’s diagnostic monitor is positioned to save lives, save provider cost in long term treatment, and open up additional opportunity to access CT Scanning.

Business / Social Impact

– Based on the American Cancer Society’s New Screening Guidelines, 3.5 million Americans are now ‘Identified’ as high risk lung cancer patients and are candidates for CT Scan screening, but > 90% of the population over 45 will not qualify until advanced symptoms occur.

– Alnion’s $50 test, in the form of a disposable (1) chip per patient, applied to those 45 years and older, represents a TAM of >$6B just in the USA. The screen would also provide justification to expand CT Scan eligibility and the all important early diagnosis for the entire population, smokers and non.

Funding Requirements

The Company is seeking a 4M USD series A capital investment to cover 3 years of normal operating expenses for the commercialization of a first product in the field of Lung Cancer. Key development work will be performed within a modest 1500 sq ft lab, while all asset intensive manufacturing will be outsourced to ISO 13485 compliant facilities.

• Alnion Ranked #1 in “Top 10 Israeli medical advances to watch in 2014”.

–Israel21C

Contact:

Steve Lerner, CEO

steve@alphaszenszor.com

+1 978-371-7084